RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:$tltff The FDA wants an option that has rates better thenenriquesuave wrote: If a patient is lying on his back, I suspect that the anterior-superior surface of the bladder may be less in full contact with the drug solution hence, if tumors are found there, they may take up less drug than fully immersed surfaces. For sure there are probably occasional contractions of bladder to 'stir up' the solution, but just trying to find some potential factors to improve outcomes. Also I hope that evaluate patients who are PR for possible UTUC early on , so as to not allow potential reseeding of bladder surface from cancer cells migrating from Upper tract to bladder. That could falsely render a patient NR rather than CR with UTUC confirmed. These small details may or may not help, but even if we increase 5-10% it makes a huge difference. I think ultimately we could partner with someone like Merck where they could combo trial TLD-1433 with Keytruda to be used on PR and NR patients. All IMHO. Best Single agent in the making and treatment with highest Quality of Life attached. Among the least amount of side effects and with One single Instillation allows for patient freedom avoidance of multiple painful invasive visits.
CancerSlayer wrote: The updated protocol/bladder volume calculation (although not perfect) should
help maximize the exposure/surface area of the inner bladder wall. However, "old" bladders tend to be less expansile & this will pose an ongoing challenge imo. I imagine over time there will be additional modifications made to help improve dosing, such as what enrique suggested (changing a patient's body position to possibly allow for more even drug distribution...this is done intraoperatively to maximize chemo treatment of certain intra-abdominal tumors that affect the inner lining of the abdomen or peritoneum). JMO.
Agree...unlike treatment response outcomes, quality of life data is often overlooked or minimized by Big pharma, & yet such data is no less important to patients. Best single agent in the making & possibly the best combo/adjuvant agent in the making. Good luck...